

Adam Cuker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4117254/publications.pdf>

Version: 2024-02-01

193
papers

10,847
citations

50276

46
h-index

33894

99
g-index

196
all docs

196
docs citations

196
times ranked

10869
citing authors

#	ARTICLE	IF	CITATIONS
1	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Medicine, 2006, 3, e270.	8.4	1,222
2	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.2	684
3	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances, 2020, 4, 4693-4738.	5.2	636
4	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine, 2017, 377, 2215-2227.	27.0	549
5	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	5.2	448
6	Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. Journal of the American College of Cardiology, 2014, 64, 1128-1139.	2.8	414
7	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2012, 120, 4160-4167.	1.4	393
8	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 2020, 50, 72-81.	2.1	362
9	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 2021, 5, 872-888.	5.2	310
10	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	2.8	285
11	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. Chest, 2017, 151, 127-138.	0.8	245
12	The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. Journal of Thrombosis and Haemostasis, 2010, 8, 2642-2650.	3.8	229
13	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. American Journal of Hematology, 2019, 94, 697-709.	4.1	225
14	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 594-622.	2.8	187
15	Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 165-186.	2.1	156
16	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 629-658.	2.8	144
17	Free Tissue Transfer in the Hypercoagulable Patient. Plastic and Reconstructive Surgery, 2012, 129, 443-453.	1.4	136
18	How I treat heparin-induced thrombocytopenia. Blood, 2012, 119, 2209-2218.	1.4	135

#	ARTICLE	IF	CITATIONS
19	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , 2017, 31, 77-84.	5.7	133
20	How I treat refractory immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1547-1554.	1.4	114
21	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014, 123, 3887-3894.	1.4	112
22	Redefining outcomes in immune TTP: an international working group consensus report. <i>Blood</i> , 2021, 137, 1855-1861.	1.4	103
23	Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia: An Integrated Approach. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 106-114.	2.7	102
24	Pathogenesis of immune thrombocytopenia. <i>Presse Medicale</i> , 2014, 43, e49-e59.	1.9	101
25	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <i>Blood</i> , 2011, 118, 6299-6305.	1.4	96
26	Clinical and laboratory diagnosis of TTP: an integrated approach. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 530-538.	2.5	96
27	Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 288-294.	2.1	92
28	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	2.8	92
29	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84
30	Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 993-994.	3.4	81
31	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 391-398.	2.1	78
32	Overuse of Computed Tomography Pulmonary Angiography in the Evaluation of Patients with Suspected Pulmonary Embolism in the Emergency Department. <i>Academic Emergency Medicine</i> , 2012, 19, 1219-1226.	1.8	75
33	Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 26-37.	2.3	74
34	Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4684-4689.	7.1	73
35	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	1.4	65
36	Immune Thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 377-384.	2.5	63

#	ARTICLE	IF	CITATIONS
37	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014, 99, 1387-1394.	3.5	63
38	Can Immune Thrombocytopenia Be Cured with Medical Therapy?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 395-404.	2.7	63
39	Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 241-247.	2.1	61
40	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. <i>Journal of Thrombosis and Hemostasis</i> , 2009, 7, 80-86.	3.8	58
41	Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2016, 1, 62-74.	5.2	58
42	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012877.	3.7	58
43	Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. <i>Thrombosis and Hemostasis</i> , 2016, 115, 1044-1055.	3.4	56
44	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	1.4	55
45	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. <i>Blood Advances</i> , 2022, 6, 664-671.	5.2	53
46	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	50
47	Toxicities of the Thrombopoietic Growth Factors. <i>Seminars in Hematology</i> , 2010, 47, 289-298.	3.4	49
48	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021, 5, 3951-3959.	5.2	49
49	Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 691-698.	2.7	48
50	Management of Periprocedural Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 217-226.	2.8	45
51	Management of the multiple phases of heparin-induced thrombocytopenia. <i>Thrombosis and Hemostasis</i> , 2016, 116, 835-842.	3.4	43
52	A cross-sectional analysis of cardiovascular disease in the hemophilia population. <i>Blood Advances</i> , 2018, 2, 1325-1333.	5.2	43
53	The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Hemostasis</i> , 2019, 17, 1956-1965.	3.8	42
54	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	5.2	42

#	ARTICLE	IF	CITATIONS
55	Novel diagnostic assays for heparin-induced thrombocytopenia. <i>Blood</i> , 2013, 121, 3727-3732.	1.4	41
56	Heparin-induced thrombocytopenia: present and future. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 353-366.	2.1	39
57	Microsurgery and the Hypercoagulable State. <i>Plastic and Reconstructive Surgery</i> , 2015, 136, 545e-552e.	1.4	38
58	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3155-3162.	5.2	38
59	Evidence-Based Mini-Review: Is Indium-Labeled Autologous Platelet Scanning Predictive of Response to Splenectomy in Patients With Chronic Immune Thrombocytopenia?. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 385-386.	2.5	37
60	Unfractionated Heparin for the Treatment of Venous Thromboembolism: Best Practices and Areas of Uncertainty. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 593-599.	2.7	37
61	Diagnostic accuracy of the <sc>PLASMIC</sc> score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and <sc>meta-analysis</sc>. <i>Transfusion</i> , 2020, 60, 2047-2057.	1.6	37
62	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. <i>Multiple Sclerosis Journal</i> , 2020, 26, 48-56.	3.0	36
63	Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders. <i>British Journal of Haematology</i> , 2015, 170, 559-563.	2.5	35
64	Controversies in the treatment of immune thrombocytopenia. <i>Current Opinion in Hematology</i> , 2016, 23, 479-485.	2.5	33
65	Thrombosis After Vaccination With Messenger RNA—1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?. <i>Annals of Internal Medicine</i> , 2021, 174, 1468-1469.	3.9	33
66	Reversal of target-specific oral anticoagulants. <i>Drug Discovery Today</i> , 2014, 19, 1465-1470.	6.4	32
67	Evidence to Decision framework provides a structured “roadmap” for making GRADE guidelines recommendations. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 103-112.	5.0	32
68	Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism. <i>Free Radical Biology and Medicine</i> , 2012, 53, 230-236.	2.9	31
69	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. <i>Annals of Internal Medicine</i> , 2022, 175, 20-28.	3.9	31
70	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. <i>British Journal of Haematology</i> , 2022, 197, 359-366.	2.5	31
71	Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. <i>Thrombosis and Haemostasis</i> , 2010, 104, 837-844.	3.4	30
72	Clot stability as a determinant of effective factor VIII replacement in hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 231-241.	2.3	30

#	ARTICLE	IF	CITATIONS
73	Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, 805-815.	4.1	29
74	ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 250-252.	2.5	28
75	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2016, 116, 42-49.	3.4	28
76	Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices. <i>American Journal of Hematology</i> , 2018, 93, 816-823.	4.1	27
77	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
78	T2 Magnetic Resonance: A Diagnostic Platform for Studying Integrated Hemostasis in Whole Blood—Proof of Concept. <i>Clinical Chemistry</i> , 2014, 60, 1174-1182.	3.2	26
79	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020, 4, 2351-2365.	5.2	26
80	Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia. <i>Current Drug Safety</i> , 2010, 5, 171-181.	0.6	25
81	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 910-919.	3.9	25
82	Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression. <i>Blood</i> , 2016, 128, 3-3.	1.4	24
83	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1533-1545.	3.8	21
84	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	5.2	21
85	Recent advances in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2011, 18, 315-322.	2.5	20
86	Current and Emerging Therapeutics for Heparin-Induced Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 31-37.	2.7	18
87	Adjuvant rituximab to prevent TTP relapse. <i>Blood</i> , 2016, 127, 2952-2953.	1.4	18
88	Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury. <i>Chest</i> , 2018, 153, 133-142.	0.8	17
89	Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 370-374.	3.8	15
90	Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12592.	2.3	15

#	ARTICLE	IF	CITATIONS
91	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 184, 58-61.	1.7	14
92	Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020, 40, 55-71.	2.6	14
93	A user guide to the American Society of Hematology clinical practice guidelines. <i>Blood Advances</i> , 2020, 4, 2095-2110.	5.2	14
94	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	3.8	14
95	Certainty of evidence and intervention's benefits and harms are key determinants of guidelines' recommendations. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 1-9.	5.0	14
96	How I manage patients with anticoagulation-associated bleeding or urgent surgery. <i>Swiss Medical Weekly</i> , 2018, 148, w14598.	1.6	14
97	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 857-865.	3.8	14
98	A Bloody Mystery. <i>New England Journal of Medicine</i> , 2009, 361, 1887-1894.	27.0	13
99	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 69-80.	2.3	13
100	Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 268-276.	2.3	12
101	Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 23-33.	5.0	12
102	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	12
103	Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 419-426.	3.1	11
104	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 24-30.	2.1	11
105	Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. <i>Blood Advances</i> , 2020, 4, 5184-5193.	5.2	11
106	Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1131-1140.	2.3	11
107	Immune Thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 377-384.	2.5	11
108	In-Hospital Complications and Readmission in Patients with Hemophilia Undergoing Hip or Knee Arthroplasty. <i>JBJS Open Access</i> , 2020, 5, e0085-e0085.	1.5	10

#	ARTICLE	IF	CITATIONS
109	Diagnosing heparin-induced thrombocytopenia: The need for accuracy and speed. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 96-102.	1.3	10
110	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	5.2	10
111	Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time. <i>Blood</i> , 2008, 112, 435-435.	1.4	10
112	Maximum 24-Hour Platelet Count Fall Rate As a Predictor of HIT. <i>Blood</i> , 2019, 134, 1072-1072.	1.4	10
113	Heparin-induced thrombocytopenia and cardiovascular surgery. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 536-544.	2.5	10
114	Rapid Evaluation of Platelet Function With T2 Magnetic Resonance. <i>American Journal of Clinical Pathology</i> , 2016, 146, 681-693.	0.7	9
115	Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 4327-4332.	5.2	9
116	Protamine-induced thrombocytopenia?. <i>Blood</i> , 2013, 121, 2818-2819.	1.4	8
117	Hospital-Acquired Thrombocytopenia. <i>Hospital Practice (1995)</i> , 2014, 42, 142-152.	1.0	8
118	Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). <i>British Journal of Haematology</i> , 2021, 194, 759-766.	2.5	8
119	Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 1-6.	2.1	7
120	Maximum 24-hour platelet count fall: Metric for improving the diagnosis of heparin-induced thrombocytopenia among patients with intermediate probability 4Ts scores. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2018-2024.	3.8	7
121	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. <i>The SPATA-DVT Study. Haematologica</i> , 2020, 105, 1948-1956.	3.5	7
122	Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2023, 98, 122-130.	4.1	7
123	The 4Ts test in the critically ill: Timing is everything. <i>Journal of Critical Care</i> , 2014, 29, 468-469.	2.2	6
124	Commentary on: Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience. <i>Aesthetic Surgery Journal</i> , 2016, 36, 67-70.	1.6	6
125	Does my patient have HIT? There should be an app for that. <i>Blood</i> , 2016, 127, 522-524.	1.4	6
126	Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. <i>Blood Advances</i> , 2020, 4, 4208-4216.	5.2	6

#	ARTICLE	IF	CITATIONS
127	Impact of gender and caregiving responsibilities on academic success in hematology. <i>Blood Advances</i> , 2020, 4, 755-761.	5.2	6
128	Optimal Medical Therapy Following Deep Venous Interventions: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 78-85.	0.5	6
129	Miniaturized T2MR Magnetic Resonance System for Analysis of Hemostasis and Detection of Impaired and Prothrombotic Blood Disorders. <i>Blood</i> , 2012, 120, 1118-1118.	1.4	6
130	ITP and TTP: interpreting evidence in light of patient values. <i>Blood</i> , 2015, 125, 1514-1515.	1.4	5
131	The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis. <i>Blood Advances</i> , 2018, 2, 1799-1802.	5.2	5
132	Diagnosing HIT: the need for speed. <i>Blood</i> , 2020, 135, 1082-1083.	1.4	5
133	Laboratory assessment of the direct oral anticoagulants: who can benefit?. <i>Kardiologia Polska</i> , 2021, 79, 622-630.	0.6	5
134	Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e845-e849.	0.4	5
135	Similarity in Joint Function Limitation in Type 3 VWD and Moderate Hemophilia A. <i>Blood</i> , 2008, 112, 426-426.	1.4	5
136	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. <i>Advances in Therapy</i> , 2021, 38, 5791-5808.	2.9	5
137	False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1224-1225.	3.4	4
138	Microfluidic hemophilia models using blood from healthy donors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 54-63.	2.3	4
139	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 115-127.	5.0	4
140	Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1279-1280.	27.0	3
141	Clinical Scoring Systems in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 447-448.	2.7	3
142	T2 Magnetic Resonance to Monitor Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 247-252.	2.7	3
143	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1490.	3.9	3
144	Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to <sc>CVS</sc> 2022 formulary changes. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3

#	ARTICLE	IF	CITATIONS
145	Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12724.	2.3	3
146	Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis. <i>Thrombosis Research</i> , 2013, 131, 244-248.	1.7	2
147	DiagnoSTic assays for heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2014, 166, 631-633.	2.5	2
148	The role of scientific publishing in the development of early career investigators. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 6-7.	2.3	2
149	Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis. <i>Annals of Hematology</i> , 2021, , 1.	1.8	2
150	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2015, 126, 761-761.	1.4	2
151	Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study. <i>Blood</i> , 2021, 138, 1015-1015.	1.4	2
152	Update in the diagnosis and management of heparin-induced thrombocytopenia. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 453-5.	0.3	2
153	Cerebral Infarction due to Severe ADAMTS-13 Deficiency with Normal Hematological Parameters: A Cause of Cryptogenic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106431.	1.6	2
154	Rate of major bleeding with ibrutinib versus bendamustineâ€¦rituximab in chronic lymphocytic leukemia: A populationâ€¦based cohort study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
155	Romiplostim: chronic therapy for a chronic disease?. <i>Blood</i> , 2009, 113, 2122-2123.	1.4	1
156	VWF sequence variants: innocent until proven guilty. <i>Blood</i> , 2012, 119, 1959-1960.	1.4	1
157	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1191-1193.	3.4	1
158	Different strokes for older folks (with TTP). <i>Blood</i> , 2019, 134, 2125-2126.	1.4	1
159	Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. , 2020, 4, 1131.		1
160	Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 3765-3765.	1.4	1
161	Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2012, 120, 267-267.	1.4	1
162	Thrombocytopenia in the Intensive Care Unit and After Solid Organ Transplantation. , 2014, , 115-132.		1

#	ARTICLE	IF	CITATIONS
163	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012). <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	2.1	1
164	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 586-586.	1.4	1
165	Autoantibodies in Heparin-Induced Thrombocytopenia. , 2014, , 511-518.		0
166	Statins for high cholesterol and for low platelets?. <i>Blood</i> , 2018, 131, 1159-1161.	1.4	0
167	Treatment of Immune Thrombocytopenia in Adults: Version 2019. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2161-2163.	3.0	0
168	Monoclonal immunoglobulin-associated C3 glomerulopathy and thrombotic microangiopathy: A real association?. <i>Journal of Onco-Nephrology</i> , 2019, 3, 3-10.	0.6	0
169	Why plasma-derived factor VIII?. <i>Haemophilia</i> , 2019, 25, e183-e185.	2.1	0
170	Development and use of clinical practice guidelines on venous thromboembolism. <i>Translational Research</i> , 2020, 225, 1-8.	5.0	0
171	Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. <i>Blood Advances</i> , 2021, 5, 2919-2924.	5.2	0
172	Immune thrombocytopenia: vaccination does not equal causation. <i>Haematologica</i> , 2021, , .	3.5	0
173	A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 69-78.	5.0	0
174	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. <i>American Heart Journal</i> , 2021, 242, 71-81.	2.7	0
175	Bleeding Symptoms and Laboratory Correlation in 150 Patients with Severe von Willebrand Disease.. <i>Blood</i> , 2007, 110, 2134-2134.	1.4	0
176	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. <i>Blood</i> , 2008, 112, 4033-4033.	1.4	0
177	Inappropriate Listing of Heparin As an Allergy in the Electronic Medical Record Due to Misdiagnosis of Heparin-Induced Thrombocytopenia: Frequency and Consequences. <i>Blood</i> , 2015, 126, 3479-3479.	1.4	0
178	Heparin-Induced Thrombocytopenia: Diagnosis and Management. , 2016, , 519-529.		0
179	Hemophilia a Clots Generated with Recombinant Factor VIIa Differed in Structure and Composition from Those Formed with Factor VIII. <i>Blood</i> , 2016, 128, 3798-3798.	1.4	0
180	Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls. <i>Blood</i> , 2016, 128, 875-875.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. <i>Blood</i> , 2018, 132, 2479-2479.	1.4	0
182	A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 5881-5881.	1.4	0
183	Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy. <i>Blood</i> , 2018, 132, 2436-2436.	1.4	0
184	How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations. <i>Blood</i> , 2018, 132, 4707-4707.	1.4	0
185	The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines. <i>Blood</i> , 2018, 132, 2237-2237.	1.4	0
186	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 2518-2518.	1.4	0
187	Near Universal Underestimation of the Risk of Recurrent Venous Thromboembolism (VTE)- an Institutional Survey of Thrombophilia. <i>Blood</i> , 2019, 134, 4978-4978.	1.4	0
188	Falsely positive heparin-induced thrombocytopenia antibody testing in severe hyperbilirubinemia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12608.	2.3	0
189	Creating Clinical Meaning for the Promis Cognitive Function Abilities Instrument: Improving Remission Outcomes for Adults with Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2021, 138, 834-834.	1.4	0
190	Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 751-751.	1.4	0
191	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. <i>Blood</i> , 2021, 138, 3039-3039.	1.4	0
192	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
193	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. <i>Blood</i> , 2020, 136, 6-8.	1.4	0